HSCT-HLHNCT07905066
Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Cumulative Incidence of First De Novo HLH Within 365 Days After Transplantation
Timeframe: From transplantation through day 365.
Discrimination of the 7-Day HLH Risk Prediction Model
Timeframe: At evaluable assessments on days 1 to 358 after transplantation, with HLH occurrence evaluated over the subsequent 7 days, through day 365.
Calibration of Predicted 7-Day HLH Risk
Timeframe: At evaluable assessments on days 1 to 358 after transplantation, with HLH occurrence evaluated over the subsequent 7 days, through day 365.
Positive Predictive Value of 7-Day HLH Alerts
Timeframe: At evaluable assessments on days 1 to 358 after transplantation, with HLH occurrence evaluated over the subsequent 7 days, through day 365.
Case Detection Rate for Incident HLH
Timeframe: At evaluable assessments on days 1 to 358 after transplantation, with HLH occurrence evaluated over the subsequent 7 days, through day 365.
Secondary (5)
Cumulative Incidence of HLH Within 100 Days After Transplantation
All-Cause Mortality Within 28 Days After HLH Onset
All-Cause Mortality Within 60 Days After HLH Onset
All-Cause Mortality Within 90 Days After HLH Onset
Overall Survival at One Year After Transplantation
Arms and interventions
Retrospective cohort
Patients whose first visit to our institution and the termination of follow-up both occurred before the opening of this study will contribute to the retrospective cohort.
Prospective cohort
Patients whose first visit to our institution occur after the opening of this study will contribute to the prospective cohort.
Retrospective/Prospective cohort
Patients whose first visit to our institution occurred before the opening of this study and whose follow-up will terminate after the opening of this study will contribute to the ambispective cohort.
Sites
1 site in 1 country
- Peking University People's HospitalBeijing, Beijing Municipality, China